• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

拉丁美洲的大肠杆菌病:一种“同一健康”多学科方法。

Escherichia coli diseases in Latin America-a 'One Health' multidisciplinary approach.

出版信息

Pathog Dis. 2017 Mar 1;75(2). doi: 10.1093/femspd/ftx012.

DOI:10.1093/femspd/ftx012
PMID:28158404
Abstract

The emergence and evolution of pathogenic Escherichia coli strains associated with animal and human infections continues being a topic of active investigation in recent years. Latin America has responded to this thread establishing the Latin American Coalition for Escherichia coli Research (LACER), a multidisciplinary group of scientists applying principles of the One Health initiative. LACER is integrating animal, human and environmental health for the mutual benefit of all, while reducing the impact of human disease. Here, I depict the usefulness of this approach by providing three examples from several priority areas in E. coli research and comparing them to the activities performed by LACER, which are enhancing collaborative efforts in biomedical research and providing a translational platform to connect with epidemiological studies and public health policy makers. The manuscript concludes with a brief historical description regarding the establishment of LACER, emphasizing the importance of collaboration between health professionals of different international organizations and not only across one specific country, to effectively combat current and future E. coli infections. The benefits of utilizing 'One Health' concepts in the establishment of LACER should encourage other professionals studying zoonotic or environmentally acquired human infections to implement effective international collaborations to combat common problems.

摘要

近年来,与动物和人类感染相关的致病性大肠杆菌菌株的出现和进化一直是一个活跃的研究课题。拉丁美洲对此做出了回应,成立了拉丁美洲大肠杆菌研究联盟(LACER),这是一个多学科的科学家团队,他们应用了“同一健康”倡议的原则。LACER 将动物、人类和环境卫生整合在一起,使所有人受益,同时减少人类疾病的影响。在这里,我通过提供大肠杆菌研究几个优先领域的三个例子来说明这种方法的有用性,并将其与 LACER 开展的活动进行比较,这些活动增强了生物医学研究的合作,并提供了一个转化平台,以与流行病学研究和公共卫生决策者联系起来。本文最后简要描述了 LACER 的成立历史,强调了不同国际组织的卫生专业人员之间合作的重要性,而不仅仅是一个特定国家内部的合作,以有效应对当前和未来的大肠杆菌感染。在 LACER 的建立中利用“同一健康”概念的好处应该鼓励其他研究人畜共患或环境获得的人类感染的专业人员实施有效的国际合作,以共同应对共同的问题。

相似文献

1
Escherichia coli diseases in Latin America-a 'One Health' multidisciplinary approach.拉丁美洲的大肠杆菌病:一种“同一健康”多学科方法。
Pathog Dis. 2017 Mar 1;75(2). doi: 10.1093/femspd/ftx012.
2
The Challenge to Control Emergence of Antibiotic Resistance in Virulent Escherichia coli Isolates in Latin America.拉丁美洲控制毒力大肠埃希菌分离株中抗生素耐药性出现的挑战。
Microbiol Spectr. 2022 Aug 31;10(4):e0150622. doi: 10.1128/spectrum.01506-22. Epub 2022 Jun 28.
3
Increasing resistance in community-acquired urinary tract infections in Latin America, five years after the implementation of national therapeutic guidelines.拉美国家在实施国家治疗指南五年后,社区获得性尿路感染的耐药性不断增加。
Int J Infect Dis. 2010 Sep;14(9):e770-4. doi: 10.1016/j.ijid.2010.02.2264. Epub 2010 Jul 15.
4
Antimicrobial resistance of Escherichia coli and therapeutic implications.大肠杆菌的抗菌耐药性及其治疗意义。
Int J Med Microbiol. 2005 Oct;295(6-7):503-11. doi: 10.1016/j.ijmm.2005.07.002.
5
Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008-2009).拉丁美洲腹腔内分离出的耐厄他培南大肠杆菌的低频率:敏感性、超广谱β-内酰胺酶的出现情况及分子特征(SMART 2008 - 2009)
J Chemother. 2012 Feb;24(1):6-11. doi: 10.1179/1120009X12Z.0000000003.
6
First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.拉丁美洲一株耐环丙沙星大肠杆菌中质粒介导的qnrA1的首次报道。
Antimicrob Agents Chemother. 2007 Apr;51(4):1527-9. doi: 10.1128/AAC.00780-06. Epub 2007 Jan 12.
7
Current perspectivesin pathogenesis and antimicrobial resistance of enteroaggregative Escherichia coli.肠聚集性大肠杆菌发病机制与抗菌药物耐药性的当前观点
Microb Pathog. 2015 Aug;85:44-9. doi: 10.1016/j.micpath.2015.06.002. Epub 2015 Jun 6.
8
Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli.大肠杆菌引起复发性尿路感染的重要细菌特征。
Dan Med Bull. 2011 Apr;58(4):B4187.
9
Recent advances in understanding enteric pathogenic Escherichia coli.对肠致病性大肠杆菌的认识的最新进展。
Clin Microbiol Rev. 2013 Oct;26(4):822-80. doi: 10.1128/CMR.00022-13.
10
Prevalence, molecular typing, and antibiotic sensitivity of enteropathogenic, enterohaemorrhagic, and verotoxigenic Escherichia coli isolated from veal calves.从犊牛中分离出的致病性大肠杆菌、出血性大肠杆菌和产志贺毒素大肠杆菌的流行情况、分子分型及抗生素敏感性
Tijdschr Diergeneeskd. 2010;135(14-15):554-8.

引用本文的文献

1
Determination of Phylogroups, Pathotypes and Antibiotic Resistance Profiles of Isolates from Freshwater and Wastewater in the City of Panama.巴拿马市淡水和废水中分离菌株的菌群、致病型及抗生素耐药谱的测定
Pathogens. 2025 Jun 20;14(7):617. doi: 10.3390/pathogens14070617.
2
Parameters for one health genomic surveillance of Escherichia coli from Australia.澳大利亚大肠杆菌“同一个健康”基因组监测参数
Nat Commun. 2025 Jan 2;16(1):17. doi: 10.1038/s41467-024-55103-2.
3
First report of the prevalence of Shiga toxinproducing Escherichia coli in ground beef in Quindío, Colombia.
哥伦比亚昆迪欧省市售绞碎牛肉中产志贺毒素大肠杆菌流行情况的首次报告。
Biomedica. 2023 Dec 1;43(4):474-482. doi: 10.7705/biomedica.7004.
4
Genomic characterization of endemic diarrheagenic Escherichia coli and Escherichia albertii from infants with diarrhea in Vietnam.越南腹泻婴儿中地方性致泻性大肠埃希菌和大肠埃希菌 albertii 的基因组特征。
PLoS Negl Trop Dis. 2023 Apr 4;17(4):e0011259. doi: 10.1371/journal.pntd.0011259. eCollection 2023 Apr.
5
Fluorescent Probe Combined with Photoelectric Analysis Technology for Detection of .荧光探针结合光电分析技术检测 。
Biosensors (Basel). 2023 Jan 18;13(2):150. doi: 10.3390/bios13020150.
6
Oral Administration with Live Attenuated Citrobacter rodentium Protects Immunocompromised Mice from Lethal Infection.口服减毒鼠伤寒沙门氏菌可保护免疫功能低下的小鼠免受致死性感染。
Infect Immun. 2022 Jul 21;90(7):e0019822. doi: 10.1128/iai.00198-22. Epub 2022 Jul 5.
7
The Challenge to Control Emergence of Antibiotic Resistance in Virulent Escherichia coli Isolates in Latin America.拉丁美洲控制毒力大肠埃希菌分离株中抗生素耐药性出现的挑战。
Microbiol Spectr. 2022 Aug 31;10(4):e0150622. doi: 10.1128/spectrum.01506-22. Epub 2022 Jun 28.
8
Operationalising Regional Cooperation for Infectious Disease Control: A Scoping Review of Regional Disease Control Bodies and Networks.实施传染病控制区域合作:对区域疾病控制机构和网络的范围界定审查
Int J Health Policy Manag. 2022 Dec 6;11(11):2392-2403. doi: 10.34172/ijhpm.2021.176. Epub 2021 Dec 26.
9
Mitotic Arrest-Deficient 2 Like 2 (MAD2L2) Interacts with Effector Protein EspF.有丝分裂停滞缺陷蛋白2样蛋白2(MAD2L2)与效应蛋白EspF相互作用。
Life (Basel). 2021 Sep 15;11(9):971. doi: 10.3390/life11090971.
10
Potential Zoonotic Pathovars of Diarrheagenic Detected in Lambs for Human Consumption from Tierra del Fuego, Argentina.在阿根廷火地岛供人类食用的羔羊中检测到的腹泻性潜在人畜共患病致病型。
Microorganisms. 2021 Aug 11;9(8):1710. doi: 10.3390/microorganisms9081710.